Repligen Corporation (RGEN)
| Market Cap | 6.96B -14.6% |
| Revenue (ttm) | 763.34M +17.4% |
| Net Income | 51.40M |
| EPS | 0.91 |
| Shares Out | 56.41M |
| PE Ratio | 135.69 |
| Forward PE | 58.77 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 948,504 |
| Open | 125.83 |
| Previous Close | 126.43 |
| Day's Range | 121.26 - 126.83 |
| 52-Week Range | 109.50 - 175.77 |
| Beta | 1.09 |
| Analysts | Buy |
| Price Target | 166.83 (+35.13%) |
| Earnings Date | May 5, 2026 |
About RGEN
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company’s products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spect... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for RGEN stock is "Buy." The 12-month stock price target is $166.83, which is an increase of 35.13% from the latest price.
News
Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference
WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in...
Repligen price target raised to $160 from $145 at Barclays
Barclays raised the firm’s price target on Repligen (RGEN) to $160 from $145 and keeps an Overweight rating on the shares.
Repligen price target lowered to $165 from $180 at JPMorgan
JPMorgan lowered the firm’s price target on Repligen (RGEN) to $165 from $180 and keeps an Overweight rating on the shares.
Repligen price target lowered to $142 from $152 at Jefferies
Jefferies analyst Matthew Stanton lowered the firm’s price target on Repligen (RGEN) to $142 from $152 and keeps a Hold rating on the shares. Q1 was “enough” against a bar
Repligen Earnings Call Transcript: Q1 2026
Q1 2026 delivered 15% revenue growth (11% organic), margin expansion, and strong performance across all segments and geographies. Guidance for 2026 was reiterated, with raised EPS outlook and continued strategic investments, including a China OEM partnership and transformation office.
Repligen raises FY26 EPS view to $1.97-$2.05 from $1.93-$2.10, consensus $1.97
Cuts FY26 revenue view to $803M-$833M from $810M-$840M, consensus $827.74M. The company said, “We also continue to make meaningful progress on our strategic priorities. We launched a Transformation Of...
Repligen reports Q1 adjusted EPS 48c, consensus 38c
Reports Q1 revenue $194.26M, consensus $192.17M. Olivier Loeillot, President and Chief Executive Officer of Repligen (RGEN) said, “We delivered a very strong start to the year, achieving 11% organic r...
Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
WALTHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fi...
Repligen to Report First Quarter 2026 Financial Results
Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00 a.m. ET Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00 a.m. ET
Repligen price target lowered to $145 from $165 at Canaccord
Canaccord lowered the firm’s price target on Repligen (RGEN) to $145 from $165 and keeps a Hold rating on the shares. The firm updated its model ahaead of Q1 results
Repligen opens new Training & Innovation Center in Netherlands
Repligen (RGEN) Corporation announced the grand opening of its new Repligen Training & Innovation Center at its OPUS Pre-packed Chromatography Columns manufacturing facility in Breda, the Netherlands....
Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its ...
Repligen initiated with a Buy at Rothschild & Co Redburn
Rothschild & Co Redburn initiated coverage of Repligen (RGEN) with a Buy rating and $160 price target The firm says Repligen is a pure-play bioprocessing company and leader in continuous
Repligen price target lowered to $145 from $175 at Barclays
Barclays analyst Luke Sergott lowered the firm’s price target on Repligen (RGEN) to $145 from $175 and keeps an Overweight rating on the shares. The firm adjusted targets in the
Repligen price target lowered to $140 from $170 at Evercore ISI
Evercore ISI analyst Daniel Markowitz lowered the firm’s price target on Repligen (RGEN) to $140 from $170 and keeps an Outperform rating on the shares as part of the firm’s
Repligen price target raised to $208 from $180 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Repligen (RGEN) to $208 from $180 and keeps a Buy rating on the shares. The firm says the company recently demonstrated “impressive”
Repligen Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Management emphasized a broad, innovative product portfolio and strong customer engagement, driving above-market growth and margin expansion. Investments in talent, analytics, and digital solutions position the company for multi-year growth, with optimism for industry tailwinds and continued operational improvements.
Repligen Transcript: Leerink Global Healthcare Conference 2026
2026 guidance targets 9%-13% organic growth, driven by a strong order pipeline and capital equipment innovation, while managing gene therapy headwinds and macroeconomic factors. Margin expansion remains a priority, with strategic investments in Asia and technology expected to yield long-term benefits.
Repligen price target lowered to $195 from $200 at UBS
UBS lowered the firm’s price target on Repligen (RGEN) to $195 from $200 and keeps a Buy rating on the shares.
Repligen price target lowered to $170 from $180 at Evercore ISI
Evercore ISI lowered the firm’s price target on Repligen (RGEN) to $170 from $180 and keeps an Outperform rating on the shares following the company’s Q4 report and FY26 guidance.
Repligen price target lowered to $180 from $190 at Wells Fargo
Wells Fargo lowered the firm’s price target on Repligen (RGEN) to $180 from $190 and keeps an Overweight rating on the shares. The firm notes the company post a solid
Repligen price target lowered to $175 from $200 at Barclays
Barclays lowered the firm’s price target on Repligen (RGEN) to $175 from $200 and keeps an Overweight rating on the shares. The firm says the company is positioned to “beat
Repligen Earnings Call Transcript: Q4 2025
Delivered strong Q4 and full-year growth, exceeding guidance with robust performance across all segments and geographies. 2026 outlook calls for 9%–13% organic growth, margin expansion, and continued investment in innovation and M&A, while monitoring macro and policy risks.
Repligen reports Q4 adjusted EPS 49c, consensus 44c
Reports Q4 revenue $197.913M, consensus $192.23M. Olivier Loeillot, President and Chief Executive Officer of Repligen (RGEN) said, “We had a great finish to 2025 with 14% organic growth in the
Repligen sees FY26 EPS $1.93-$2.01, consensus $2.07
Sees FY26 revenue $810M-$840M, consensus $823.87M